Genentech's Enspryng Becomes First At-Home Subcutaneous Option for Thyroid Eye Disease

Genentech received FDA approval for Enspryng (satralizumab) to treat adults with thyroid eye disease, making it the first at-home subcutaneous option for the condition. TradingView reported the approval followed Phase III SatraGO data and a priority review, with no new safety signals reported.

How the Enspryng Approval Unfolded

Genentech is a US-based biotechnology subsidiary of Roche Holding AG that develops and commercializes biologic and small-molecule medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic disease, according to company records. The FDA approved Enspryng for adults with thyroid eye disease, a rare ophthalmology disorder.

The approval was based on Phase III SatraGO data and was granted under priority review. No new safety signals were reported. Enspryng is the first at-home subcutaneous option for thyroid eye disease, distinguishing it from infusion therapies that require clinical site visits.

Genentech also has a supplemental biologics license application for MOGAD under priority review, with a next decision expected in January 2027.

Genentech's Recent Regulatory Record

Genentech's recent regulatory actions include the FDA approval of Tecentriq and Tecentriq Hybreza as the first ctDNA MRD-guided adjuvant therapy for muscle-invasive bladder cancer in patients identified by Natera's Signatera CDx, marking Tecentriq's 11th U.S. indication, according to akta.pro company records. The FDA also approved Venclexta (venetoclax) in combination with acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated chronic lymphocytic leukemia.

Earlier Genentech Developments

On October 14, 2026, Biocon entered a global settlement and license agreement with Genentech, securing earliest launch dates for Pebrilzo, its biosimilar to Perjeta, resolving pending patent disputes in the U.S., Canada, and other jurisdictions, with EU/UK launches in Q1 CY2027, ScanX reported. On October 5, 2026, Alector granted Genentech exclusive global rights to develop and commercialize AL050, a brain-penetrant GCase enzyme replacement therapy for Parkinson's disease, for $100 million upfront, Stock Titan reported. On September 28, 2026, Genentech broke ground on a $750 million manufacturing expansion in Hillsboro, Oregon, adding 211,000 square feet to double the site's size, Stock Titan reported.

What Comes Next for Enspryng

The MOGAD supplemental biologics license application remains under priority review, with a next decision expected in January 2027.